Sunshine Biopharma Inc Q2 2026 Earnings: Miss on EPS and Revenue

Sunshine Biopharma Inc (SBFM) reported Q2 2026 earnings that missed analyst expectations on both earnings per share and revenue, with the company posting a loss of $0.54 per share against estimates of $0.28 per share.

The biotechnology company’s EPS of -$0.54 represented a negative surprise of 96.08%, significantly worse than the consensus estimate of -$0.28. This marked a substantial miss on the bottom line for the quarter ended in Q2 2026.

Revenue for the quarter came in at $8.58 million, falling short of analyst expectations of $10.20 million. The revenue miss of 15.91% indicates the company generated $1.62 million less than anticipated by Wall Street analysts.

The dual miss on both EPS and revenue metrics suggests operational challenges for Sunshine Biopharma during the second quarter of fiscal 2026. The company’s actual loss per share was nearly double the expected loss, while revenue underperformed by approximately $1.6 million.

This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.